Mitomycin C (MC) is a well-known DNA alkylating agent. MC analog, 10-decarbamoyl mitomycin C (DMC), unlike MC, has stronger effects on cancer with p53 mutation. We previously demonstrated that MC/DMC could activate p21 WAF1/CIP1 in MCF-7 (p53-proficient) and K562 (p53-deficient) cells in a p53-independent mode. This study aimed to elucidate the upstream signaling pathway of 
| INTRODUCTION
Mitomycin C (MC) is a well-known anti-cancer drug and is commonly used to treat various cancers, such as lung, ovary, breast, and cervical cancers. [1] MC alkylates DNA selectively at several sites. The current consensus is that MC cytotoxicity is mainly due to its ability to form Interstrand Crosslinks (ICLs) between exocyclic amino groups of deoxyguanosine residues located on opposing DNA strands. However, MC is only very effective on treating p53-proficient cancer cells which represent only about 50% of human cancers. [2] Interestingly, 10-decarbamoyl mitomycin C (DMC), which is a MC analog lacking the carbamoyl on C10, is able to induce a p53-independent cell death. [3] The detailed mechanism of this discrepancy on the pharmacological effects of MC and DMC is still unclear. A recent study has indicated that p21 WAF1/CIP1 is involved in the p53-independent mode of cell death triggered by MC and DMC. [4] Delineating the upstream regulator of p21 WAF1/CIP1 in response to MC and DMC will enhance our understanding of these mitomycins' pharmacological mechanisms. Studies also suggest p21 WAF1/CIP1 plays a dual role in regulating cell survival or cell death. [5] [6] [7] p21 WAF1/CIP1 is a negative cell cycle regulator via the inhibition of cyclin-dependent kinases which consequently triggers cell cycle arrest and inhibits cell proliferation. [8, 9] In contrast, elevated p21 WAF1/ CIP1 also correlates with chemo-resistance in cancer. For instance, higher level of p21 WAF1/CIP1 is found in glioblastoma patients and glioblastoma exhibits a strong resistance to chemotherapy. [10, 11] The expression of p21 WAF1/CIP1 is mainly regulated by the p53 tumor suppressor which is an important player in apoptosis. Other signaling proteins, such as Akt and c-Myc, can also regulate p21 WAF1/CIP1 expression in a p53-independent mode. [12, 13] However, the cellular mechanisms involved in regulating p21 WAF1/CIP1 in a p53-dependent and/ or p53-independent manner in response to stress or chemicals is not fully understood. Akt, a member of the serine and threonine kinase family, has a key role in promoting and maintaining cell survival. Several studies have demonstrated that the phosphatidylinositol 3-kinase (PI3K)/Akt pathway could be a target of chemotherapy. [14] [15] [16] Zhang et al. [16] unveiled the new function of Akt in regulating the cell cycle progression of G2/M phase and its association with DNA damage and repair. Akt is also associated with p21 WAF1/CIP1 function by phosphorylating p21 WAF1/CIP1 at Thr145 to retain p21 WAF1/CIP1 in the cytosol. [17] In this study, we investigated the role of Akt in response to MC and DMC in p53-proficient cell line (MCF-7) and p53-deficient cell line (K562). The relationship between Akt and p21 WAF1/CIP1 activation by MC and DMC in these two cell lines was also elucidated. These findings shed a light on the pharmacological mechanisms of MC and DMC in p53-dependent and p53-independent modes of cell death.
| METHODS AND MATERIALS

| Cell culture and reagents
Human breast cancer MCF-7 (p53-proficient) and human leukemia K562 (p53-deficient) cell lines obtained from American Cell Tissue Culture (Manassas, VA, USA) were used in this study. These cell lines have been used for MC and DMC studies by various research groups. [3, 4] MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), and 50 μg/ml gentamicin. K562 cells were cultured within RPMI 1640 10% FBS, 2 mM glutamine, and 50 μg/ ml gentamicin. Cell culture reagents such as DMEM, RPMI 1640, FBS, gentamicin were obtained from Thermo Fisher Scientific. Both cell lines were maintained in an incubator at 37°C and 5% CO 2 . On the day before chemical exposure, cells were cultured into 60-mm Petri dishes. Cells with about 80% confluence were then ready for chemical exposure.
Mitomycin C (MC) was a generous gift from Prof. M. Tomasz. 10-Decarbamoyl mitomycin C (DMC) was synthesized following Kinoshita's protocol. [18] The major cytotoxic MC-DNA adduct, the α-ICL (Figure 1 ), was synthesized as previously described. [4] Mammalian Protein Extraction reagent (M-PER) lysis buffer and Halt protease/phosphatase inhibitor cocktail 
| Chemical treatment
MC and DMC solutions were prepared 15 min before experiments in cell culture media. The chosen dosages (5, 10, 50, and 75 μM) were based on previous studies. [4, 19] Cells treated with chemicals were incubated at 37°C for 24 hr.
| Western blot analysis
After chemical treatments, cells were lysed by M-PER lysis buffer supplemented with Halt protease/phosphatase inhibitor cocktail following the manufacturer's protocol. Protein concentration was determined by Bio-Rad DC reagents using bovine serum albumin (BSA) to set up a calibration curve. Western blot analysis was performed as previously described. [20] Briefly, forty (40) μg of total proteins from cell lysates was subjected onto 8% sodium dodecyl sulfate polyacrylamide gel for protein separations via electrophoresis. After separation, proteins were then transferred onto polyvinylidene fluoride (PVDF) blotting membranes for immunoblotting. Membranes were blocked with 5% BSA in phosphate-buffered saline and 0.05% Tween-20 (5% BSA in PBS/0.05% Tween-20) for 1 hr at room temperature with shaking. Then, membranes were incubated with primary antibody at 1 μg/μl overnight at 4°C with shaking. After incubating with primary antibody, corresponding horseradish peroxidase-linked secondary antibody was applied for 1 hr at room temperature with shaking. Membranes were developed using Super Signal West Pico Chemiluminescent Substrate detection reagents (Rockford, IL). Chemilluminescent signals were captured using the Geliance 600 imaging system (PerkinElmer, Shelton, CT) and analyzed by GeneTools software (Syngene, Frederick, MD). After obtaining the data for the first target protein, membranes were then stripped with Stripping buffer for 15 min at room temperature and re-probed with β-actin (1 μg/μl), Akt or p21 WAF1/CIP1 antibodies (1 μg/μl) as the loading control.
| Transfection
Transfection of short hairpin RNA of p53 (p53 shRNA) from Santa Cruz to knockdown the expression of p53 transiently was performed as previously described. [4] Briefly, p53 shRNA plasmid was mixed with SuperFect ™ reagent in a ratio of 1 μg DNA, 2 μl transfection reagent, and 30 μl of serum free DMEM for 10 min at room temperature according to the manufacturer's protocol. After 10 min, 0.6 ml of cell culture media was added to the mixture and transferred to the cells for a 3-hr incubation at 37°C. The transfection mixtures were then removed and replaced with cell culture media after washing the cells with PBS twice. The cells were then incubated for an additional 24 hr at 37°C in humidified air containing 5% CO 2 prior to chemical treatments. We have previously evaluated the efficiency of p53 knockdown and showed that p53 shRNA has lowered p53 protein expression by about 73.6%. [4] The α-interstrand cross-link which was synthesized as previously described was also transfected into cells by SuperFect ™ transfection reagent using the same protocol as p53 shRNA plasmid transfection. [4] 2.5 | Protein expression profiles of MCF-
and K562 cells treated with MC and DMC
The proteomics profiling analysis was performed using the label-free quantitation (LFQ) method using modified protocols originally described in detail in other proteomics research papers. [21, 22] The comprehensive comparative proteomics profiling of MCF-7 and K562 treated with MC and DMC is the subject of another manuscript. We report herein the key findings regarding the modulation of PI3K/ Akt signaling pathway in MCF-7 and K562 treated with MC and DMC.
| Sample preparation and nanoLC/ MS/MS
Total protein concentration from each total cell lysate obtained from the control or drug-treated MCF-7 and K562 cells samples was determined using the Bradford microassay. Equal protein amounts (50 μg), prepared in technical triplicates, were reduced in 25 mM DTT (Thermo Scientific) in 50 mM ammonium bicarbonate buffer, at pH 8.5, for 55 min at 55°C. The reduced proteins were further alkylated with 150 mM iodoacetamide solution, in the dark, for 50 min at room temperature. Three different enzymes were used for "in solution" digestion in 50 mM ammonium bicarbonate buffer, pH 8.5, for 18 hr, at 37°C: endoproteinase Lys-C (1:50 enzyme: protein ratio); trypsin (1:20 enzyme: protein ratio) and Glu-C (1:10 enzyme: protein ratio) (sequencing grade Promega, Madison, WI, USA). The peptides mixture, extracted from all enzymatic digestions, were desalted on C18 Prep clean columns before high-resolution liquid chromatography tandem mass spectrometry (LC-MS/MS). The reversed-purified peptide mixtures were subjected to nanoLC-MS/MS sequencing on a LTQ-Orbitrap Velos HR mass spectrometer using the HCD fragmentation method. All samples were run in triplicate to perform label-free quantitation.
| Protein identification
Raw files from each technical and biological replicate were filtered, de novo sequenced and assigned with protein ID using Peaks 8.5 software (Bioinformatics Solutions, Waterloo, Canada), by searching against the human (Homo Sapiens) Swiss-Prot database (January 2017; 158,154 entries). The following search parameters were applied for LFQ analysis: for each LysC, trypsin, and GluC, we allowed one missed cleavage at one peptide end. The parent mass tolerance was set to 18 ppm using monoisotopic mass, and fragment ion mass tolerance was set to 0.5 Da. Carbamidomethyl cysteine (+57.0215 on C) was specified in PEAKS 8.0 as a fixed modification. Methionine, lysine, proline, arginine, cysteine, and asparagine oxidations (+15.99 on CKMNPR), deamidation of asparagine and glutamine (NQ-0.98) and pyro-Glu from glutamine (Q-18.01N-term) were set as variable modifications. Data were validated using the FDR method built in PEAKS 8.5, and protein identifications were accepted with a confidence score (−10lgP)> 15 for peptides and (−10lgP)> 15 for proteins; a minimum of 1 peptide per protein after data were filtered for <1.0% FDR for peptides and less than 1.5% FDR for proteins identifications (p < 0.05).
| Label-free relative peptide quantification (LFQ)
The PEAKS Q module implemented in the PEAKS 8.5 proteomics software (Bioinformatics Solutions Inc, Waterloo, ON Canada) was applied to assess the differential protein expression profiles in MCF-7 and K562 cells treated with 50 μM MC and 50 μM DMC for 24 hr. Using the LFQ module, the relative protein abundances were exported for further processing after normalization of the corresponding averaged MS1 areas (i.e. abundances) with respect to the total ion current (TIC) and with respect to the total abundance of actin, which showed no changes during drug treatment.
| Gene ontology (GO), molecular, and cellular pathways enrichment analysis
Networks, functional analyses, biochemical, and cellular pathways were generated using the ingenuity pathway analysis (IPA; Ingenuity Systems, Redwood City, CA, USA) and the list of proteins extracted from PEAKS DB searches, together with their experimentally determined ratios corresponding to the protein abundances extracted from the LFQ analysis. Specifically, the abundance ratios of each quantifiable protein from MC and DMC treated MCF-7 and K562 cells versus control, untreated samples, were used to calculate the experimental fold changes by rescaling their values using a log2 transformation, such that positive values reflected fold increases while the negative values reflected fold decreases. This mathematical transformation for calculating the fold changes in the protein expression profiles was performed in IPA. For network generation, datasets containing gene identifiers (gene symbols) were uploaded into the IPA application together with their rescaled log2 transformation of protein's area ratios. These molecules were overlaid onto a global molecular network contained in the Ingenuity Knowledge Base. The networks were then algorithmically generated based on their connectivity index using the built-in IPA algorithm. The probability of having a relationship between each IPA indexed biological function and the experimentally determined genes were calculated by a right-tailed Fisher's exact test. The level of significance was set to a p-value of < 0.05. Accordingly, the IPA analysis identified the molecular and cellular pathways from the IPA library of canonical pathways that were most significant to the dataset (−log (p value)> 2.0). For the quantitative analysis of the expression profiles, IPA assigned the "z-score" function to all eligible canonical and cellular pathways (where a "z < −2.0" represent significant down-regulation while a z > 2.0 represent a significant upregulation of the selected pathway). The proteins associated with the canonical PI3K/Akt signaling pathway were assigned to each proteome dataset using the IPA related database and are presented in the Supporting Information Figure S1 .
| Statistics
The results are reported as means ± SEM of at least three independent experiments. Statistical significance was determined using one-way analysis of variance (ANOVA) and then followed by Dunnett's post hoc test (p < 0.05, with control at 100%) using Graphpad prISM ® 6 software.
| RESULTS AND DISCUSSION
Mitomycin C (MC), a powerful antibiotic produced by Streptomyces casepitosus, is used to treat various cancers,
especially p53-expressed cancers. Interestingly, MC analog, 10-decarbamoyl mitomycin C (DMC), which is just lacking the carbamate on C10, exhibits stronger pharmacological effects toward p53-mutated cancers. Cheng et al. [4] demonstrated that the involvement of p21 WAF1/CIP1 in MCF-7
(p53-expressed) and K562 (p53-mutated) cells in response to MC and DMC exposures is p53 independent. The aim of this study was to delineate the upstream signaling pathway of p21 WAF1/CIP1 activation in response to MC and DMC. In addition to p53, Akt also plays a crucial role in regulating p21 WAF1/CIP1 activity. The phosphatidylinositol 3-kinase/Akt/ mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway is often activated in cancer. [23] [24] [25] Therefore, Akt has been an appealing target of chemotherapy. [12, 26] Phosphorylation of Akt at Ser 473 is required for Akt activation which subsequently can phosphorylate p21 WAF1/CIP1 to deactivate p21 WAF1/CIP1
. [27] As MC and DMC have the ability to deactivate p21 WAF1/CIP1 in MCF-7 and K562 cells, we hypothesized that the phosphorylation status of Akt would be decreased in cells treated with MC and DMC.
| Deactivation of Akt by MC and DMC in MCF-7, but not in K562 cells
To delineate the upstream signaling molecule of p21
activation by MC and DMC, the status of Akt activation was investigated by Western blot analysis to detect the phosphorylation of Akt at Ser473. The results showed that the level of phosphorylated Akt was significantly decreased in MCF-7 cells treated with 50 and 75 μM MC for 24 hr (Figure 2a ). When MCF-7 cells were treated with DMC at 50 and 75 μM for 24 hr, the level of phosphorylated Akt was also significantly reduced (Figure 2a ). However, when K562 cells were treated with MC and DMC for 24 hr, the level of the phosphorylated Akt showed no change ( Figure 2b ). Akt has been suggested to regulate cell proliferation and cell cycle progression in p53-dependent and p53-independent manners. [12, 13, 28] As the K562 cell line has an inactivation p53 mutation in exon 5, [29] the decreased level of phosphorylated Akt by MC and DMC in MCF-7 cells could be a p53-dependent action.
| Deactivation of Akt by MMC and DMC in MCF-7 cells is p53 dependent
It is suggested that checkpoint kinase 1 (Chk1) activation and G2/M phase arrest triggered by cisplatin (another potent anticancer drug and DNA cross-linking agent) requires Akt activation in a p53-independent manner. [30] However, Duan et al. [30] demonstrated that cisplatin activates Akt in p53-proficient and p53-deficient osteosarcoma cell lines. Gottlieb et al. [14] demonstrated that there is a crosstalk between p53
and Akt in the determination of cell fate in response to stress. They have showed that the dysregulation of Akt by p53 can obstruct Mdm2 function and subsequently hinder p53 inhibition by Mdm2. Therefore, MC and DMC could dephosphorylate Akt in the p53-dependent manner.
To elucidate the role of p53 in the dephosphorylation of Akt by MC and DMC in MCF-7 cells, p53 shRNA was used to knock down the expression of p53. After p53 shRNA knockdown, MCF-7 cells were treated with 75 μM MC and DMC for 24 hr. The level of phosphorylated Akt was determined by Western blot analysis. The results in Figure 3 showed that MCF-7 with p53 knockdown did not lower the phosphorylated Akt level in response to MC and DMC. This indicated that deactivation of Akt by MC and DMC in MCF-7 cells is p53 dependent. Interestingly, Duan et al. [30] also showed that Akt inhibitor can potentiate cisplatin-induced apoptosis in p53-proficient osteosarcoma cells, but not p53-deficient osteosarcoma cells.
| Effect of the α-interstrand crosslink (α-ICL) on Akt activity
Both mitomycins, MC and DMC, are DNA alkylating agents. MC and DMC cause DNA damage through the formation of DNA mono-adducts, as well as interstrand cross-links (ICLs) [31, 32] between exocyclic amino groups of deoxyguanosine residues located on opposing DNA strands. The major ICLs produced by MC and DMC in mammalian DNA have opposite stereochemistry: while MC generates an ICL with a trans stereochemistry at C1" (α-ICL); DMC produces an ICL with a cis stereochemistry at C1" (β-ICL) (Figure 1 ). Both the α-ICL and β-ICL are primarily responsible for the cytotoxicities of the mitomycins. [33, 34] The α-ICL itself has the potential to activate p21 WAF1/ CIP1 . [4] Therefore, it is possible that the α-ICL itself can regulate Akt phosphorylation which then affect p21 WAF1/ CIP1 activity. In order to examine the effect of the α-ICL on Akt, MCF-7 cells were transfected with 1 and 3 μg of the α-ICL and the level of phosphorylated Akt was detected by Western blot analysis. The results in Figure 4 showed that the α-ICL did slightly decrease the level of phosphorylated Akt, but not as much as MC by itself. This indicated that α-ICL might be involved in the MC triggered dysregulation of Akt. In Cheng's study, [4] only cells treated with 5 μg of α-ICL showed p21 WAF1/CIP1 activation. Therefore, higher amount of the α-ICL will need to be introduced into cells in order to exhibit a significant response. . MC and DMC have been shown to lower the level of phosphosylated p21 WAF1/CIP1 and to dephosphorylate Akt in this study. [4] In order to investigate the relationship of Akt and p21 WAF1/ CIP1 in response to MC and DMC, Akt activator (SC79) was used. SC79 is an effective Akt activator used to enhance the phosphorylation of Akt at Ser473. [35] MCF-7 Cells were pretreated with SC79 (8 μg/ml) for 30 min before exposure to MC and DMC for 24 hr. Akt activity was increased when cells were exposed to SC79 (Figure 5a ). However, the decreased level of the phosphorylated p21 WAF1/CIP1 by MC and DMC was not attenuated by Akt activator (Figure 5b ). This result showed that the deactivation of Akt by MC and DMC is not responsible for the activation of p21 WAF1/CIP1 triggered by MC and DMC in MCF-7 cells. Faes and Dormond [36] suggested that inhibiting the PI3K/ Akt signaling pathway can be a favorable cancer therapy approach. Many downstream effectors of Akt, such as FOXO, BAD, TSC2, p21
|
, and p27, play critical roles in cell growth, proliferation, and survival. [36, 37] As p21 WAF1/CIP1 activation by MC and DMC is not associated with deactivation of Akt, other downstream effectors of Akt might be responsible for MC and DMC triggered cell death in MCF-7 cells. On the other hand, phosphorylation of p21 WAF1/CIP1 can be regulated by different kinases. [6, 38] Akt is the main one on phosphorylating p21 WAF1/CIP1 on Thr145 site to promote cell survival and proliferation. Protein kinase A (PKA) is another kinase which can phosphorylate p21 WAF1/CIP1 on Thr145 site to facilitate anti-apoptotic activity. Protein kinase C (PKC) can also phosphorylate p21; however, the site of phosphorylation is on Ser146 in this case. Phosphorylation of p21 on Ser146 is related to p21 stability. Cheng et al. [4] demonstrated that MC and DMC dephosphorylate p21 on Thr145, not on Ser146. So PKA could be the upstream signaling molecule to regulate p21 responses to MC and DMC.
| Proteomic profiling analysis reveals that DMC has a stronger effect on deactivating PI3K/Akt signaling pathway in MCF-7 cells
To further explore the cellular pathways that could be interconnected with the changes in the phosphorylation state of Akt, and to reveal a wider perspective on the changes in the cellular pathways in response to the treatment with MC and DMC, we developed and optimized label-free quantitative (LFQ) proteomics coupled with bioinformatics analysis of MCF-7 and K562 cells treated with 50 μM of MC and DMC. We used label-free global proteomic profiling to increase our knowledge about the cellular and biochemical pathways regulated by MC and DMC in these two cancer cell lines. The proteomics platform employed the nano/LC-ESI MS/MS sequencing of tryptic/Glu-C/Lys-C generated peptides from total cell lysates, as well as a Q-Exactive quadrupole orbitrap mass spectrometer coupled with the LFQ method for data analysis built in the PEAKS 8.0/8.5 software from Bioinformatics Solutions, Inc. IPA and bioinformatics analysis enabled the layout of a model for the up-regulation or down-regulation of canonical biochemical and cellular pathways based on the observed changes in the protein expression profiles of proteins mapped by proteomics. The built-in bioinformatics algorithm in IPA assigned an "activation z score" where z scores higher than 2.0 and < −2.0 predicts significant changes in the activation or inhibition of a selected pathway, respectively (see the materials and methods section for details). IPA and bioinformatics analysis predicted a significant increase in the cell death of MCF-7 and K562 cancer cells treated with either drug MC, or DMC. This was projected most likely to be accomplished by up-or downregulation of many key proteins involved in a wide variety of cellular pathways that mediate the inhibition of tumor cell proliferation (manuscript under preparation). Therefore, the results obtained from the global label-free proteomic profiling complemented other results from system biology's techniques, and highlighted the broad effects of these drugs and their potential use as chemotherapeutics. This chemotherapeutic Figure S1 . Specifically, IPA predicted that DMC induced down-regulation of PI3K/Akt signaling pathway in MCF-7 cells (the activation z score for the pathway is "−1.5", p < 0.05), as shown in Figure 6a and Supporting Information Figure S1 . Remarkably, the Akt serine/threonine kinase 1 was shown to have a lower protein expression profile characterized by a "-1.462" fold change in DMC treated versus control, untreated MCF-7. In contrast with the DMC induced downregulation of PI3K/Akt signaling pathway in MCF-7 cells, IPA predicted no significant effect of MC treatment on the PI3K/ Akt signaling pathway in MCF-7cells (the z score is +0.782, p > 0.05) (Figure 6c and Supporting Information Figure S1 ). In sharp contrast with the reported and discussed activities in MCF-7, MC, and DMC showed no significant effect on Akt signaling in K562 leukemia cells (Figure 6b,d and Supporting Information Figure S1 ). As shown in Figure 6b and the data presented in its associated Supporting Information Figure S1 , IPA predicted no significant effect of DMC treatment on PI3K/Akt signaling pathway in K562 cells (the z score is +0.832, p > 0.05), and this contrasts sharply with its discussed effect in MCF-7 (Figure 6a) . Moreover, the pro-survival protein, Bcl-XL, was predicted to be significantly up-regulated in the DMC treated versus control ("+18.805" fold change), suggesting that DMC is not a potent activator of apoptosis in K562 cells. Moreover, a similar effect was predicted by the same bioinformatic analysis to characterize the effect of MC treatment on PI3K/Akt signaling pathway in K562 cells (the z score is −0.277, p > 0.05). Additionally, the pro-survival protein,
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Mitomycin C F I G U R E 6 IPA predicted effect of (50 μM) MC and (50 μM) DMC on PI3K/Akt signaling pathways in MCF-7 and K562 cells. The proteins mapped by IPA to be part of the PI3K/Akt signaling pathway are presented as gene symbols. The fold changes corresponding to each protein mapped to the pathway are calculated using the corresponding protein abundance ratios (MS1 area from LFQ analysis), defined by the MC or DMC Treatment versus Control (untreated) in each sample. Proteins identified by LFQ proteomics are marked with purple while their selected fold changes (lower than "−1.4" or higher than "+1.4) are shown inside boxes. The protein expression profiles were normalized to cytoplasmic actin by the LFQ method built-in PEAKS Q module (version 8.0); green defines the down-regulated expression profiles; red defines the upregulated. Details on the proteins from the pathway and their associated expression profiles are included in the Supporting Information Figure S1 . Bcl-XL, was predicted to be significantly up-regulated in the MC treated versus control ("+17.949" fold change), suggesting that MC is not a potent activator of apoptosis in K562 cells (Figure 6d and Supporting Information Figure  S1 ). However, the LFQ proteomics analysis revealed that both drugs trigger other important biochemical and cellular pathways, and this offers additional support for the complementary use of these pharmacological agents to modulate the activity of other chemotherapeutic agents used to treat leukemia (C. C Clement, S-Y. Cheng, A. Vargas, J-Y. Lee, E. Champeil, unpublished results). The comprehensive analysis of the pharmacoproteomic results describing the opposite effects of MC and DMC in MCF-7 breast cancer in contrast to their modulatory effects in K562 leukemia cancer cells are the subject of an independent research communication.
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| Identification of potential Akt connected pathways involved in the cytotoxicity of MC and DMC by proteomics profiling analysis
In addition to the observed direct effects of MC and DMC on the level of protein expression of Akt kinase, the bioinformatics integrative analysis predicted that many other proteins from the Akt/PI3K pathways could play a significant role in the MC and DMC mediated cytotoxicity in MCF-7 and K562 cells. Because of the complex and interrelated networks of cellular signaling and signal transduction within the PI3K/Akt pathway, and its interconnection with other pathways that coordinate to preserve the survival of cancer cells, it is important to conduct a global proteomics assessment of MC and DMC effects on a wider landscape of signaling molecules, rather than focusing on only one or two proteins such as p53 and Akt. As such, it is important to mention that the IPA analysis predicted that in conjunction with the Akt/PI3K signaling several potential signaling players were notably regulated by MC and DMC in MCF-7 cells and K562 cells and listed in Tables 1  and 2 , respectively. Most of the listed proteins, Akt, CDC37, 14-3-3, GRB2, play important roles in cell proliferation and growth (https://www.proteinatlas.org/). NF kappa B and HRas are also on the list and are important for cancer initiation and progression (https://www.proteinatlas.org/). Only Bcl-XL has a unique role in anti-apoptosis (https://www.proteinatlas.org/).
| Changes in the proteome of MC and DMC treated MCF-7 cells
Among of these proteins listed, MC dramatically downregulated NF kappa B (calculated expression level "−17.6"), 14-3-3 proteins (calculated expression level "−18.9"), and GRB2 (calculated expression level "−16.2") in MCF-7 cells.
MC also increased HRas expression in MCF-7 cells (calculated expression level "+2.62"). Upon treatment with DMC, HRas (calculated expression level "−2.99") and the 14-3-3 proteins (calculated expression level "−6.2") were notably down-regulated. With GRB2, DMC up-regulated its expression (calculated expression level "+2.21"). Both MC and DMC have no effect on Bcl-XL expression in MCF-7 cells. These results support our recently reported contradictory effects of MC and DMC in MCF-7 cancer cells, as already described above for other signaling molecules and could help to further explore the effect of these two drugs on EGFR-GRB2-RAS signaling pathway. All these data are shown in Table 1 , Figure 6a ,c, and Supporting Information Figure S1 .
| Changes in the proteome of MC and DMC treated K-562 cells
The 14-3-3 proteins were considerably decreased with calculated expression level "−2.4." For K562 cells treated with DMC, HRas (calculated expression level "+2.206") was noticeably increased, and the 14-3-3 proteins were extensively down-regulated (calculated expression level "−21.1"). This indicates that DMC has stronger cytotoxic effects on K562 cells. Interestingly, both MC and DMC induced significant up-regulation of Bcl-XL (calculated expression level "+17.95" for MC and "+18.80" for DMC) in K562 cells. This suggests that MC and DMC may trigger non-apoptotic cell death in K562 cells. Further validations will be conducted to confirm these findings. All these data are shown in Table 2 , Figure 6b ,d, and Supporting Information Figure S1 .
Altogether, the coordinated and/or opposite effects of MC and DMC in MCF-7 breast and K562 leukemia cancer cells support the more cytotoxic effect of MC in MCF-7 in contrast to the more potent effect of DMC in K562 and reinforce the need to explore the complex PI3K/Akt cell signaling interactome by focusing on the level of protein expression and the associated regulatory mechanisms characterizing all signaling and adaptor molecules involved in the PI3K/Akt pathway.
The proteomics data were validated by the Western blotting analysis of total and phosphorylated Akt in the case of each treatment as already described above, in another section of the results. Notably, the Western blotting presented in Figures 2-5 reveals that the level of non-phosphorylated Akt is also affected by the dose and the type of drug treatment, in addition to the level of phosphorylated Akt. One possible mechanism that could explain these data may involve the alkylation-induced DNA damage of the Akt gene, even though other steps cooperating to the Akt expression could also be part of the mechanism of down-regulating this kinase, although the changes in the posttranslational modification states of Akt, such as drug mediated enhanced ubiquitination, followed by degradation cannot be excluded. It was shown that following the PIP3-mediated activation at the membrane, the activated Akt is subjected to other regulatory events, including ubiquitination-mediated deactivation, [39] and we can hypothesize that this would be another possible mechanism of MC and DMC induced deactivation in p53-dependent MCF-7 cells. The proteomic LFQ analysis employed was designed to generate the first global pharmacoproteomics fingerprints for MC and DMC activities in MCF-7 and K562 cancer cells and was not intended to profile the enriched phosphoproteome landscape for each drug treatment. However, future work on the enriched phosphorylation fractions from the total cell lysates of MCF-7 and K562 will further validate the major kinases and their corresponding substrates affected by MC and DMC in both selected breast and leukemia cell lines.
Nevertheless, the global and label-free proteomic profiling presented herein extend and update our understanding of previously reported contradictory effects of some anticancer drugs and ionizing radiation on activation of PI3K/Akt pathway in breast cancer cells. For example, it has been shown that doxorubicin can induce significant phosphorylation and activation of Akt in MCF-7 breast cancer cells. [40] Moreover, this activation of Akt pathway is not limited to doxorubicin or ionizing radiation. For example, the treatment of MCF-7 cells with several different drugs (paclitaxel, 5-flurouracil and gemcitabine) that act through different mechanisms can also induce Akt phosphorylation, although the response, timing, and dose required for this effect varied among the drugs tested. [41] In addition, cellular stress, including hypoxia and ultraviolet radiation, has been reported by others to induce PI3K-dependent Akt activation. [42] This Akt activation was proposed to be a defensive mechanism approach undertaken by the tumor cells against external detrimental stimuli and justified novel chemotherapeutic approaches of targeting the PI3-K/Akt for further chemosensitization or radiosensitization. [42] Our data show that the DMC treatment of MCF-7 down-regulated both the total Akt and the phosphorylated Akt, and these data suggest it is possible DMC would serve as a superior drug for enhancing the chemosensitization or radiosensitization of MCF-7 breast cancer cells. However, the effects of other potential signaling molecules regulated by MC and DMC on chemotherapy should also be included into the consideration of the overall pharmacological outcomes of drugs.
| CONCLUSIONS
In this study, we investigated the role of Akt in MCF-7 and K562 cells in response to MC and DMC. The deactivation of Akt in response to MC and DMC was observed in MCF-7 cells, but not in K562 cells. By knocking down p53 in MCF-7 cells, the deactivation of Akt by MC and DMC was confirmed to be p53 dependent. When MCF-7 cells were treated with the main MC-produced ICL (α-ICL), there was only slight changes in the level of the phosphorylated Akt. Higher dosages of α-ICL will need to be used to investigate the effect of α-ICL on Akt activity. With the Akt activator (SC79), MC and DMC can still induce p21 WAF1/CIP1 activation. Therefore, p21 WAF1/CIP1 is not the down-stream effector of the deactivated Akt triggered by MC and DMC in MCF-7 cells. In this research study, we also reported for the first time a label-free pharmacoproteomic platform aimed to delineate the differential potential of MC and DMC for inducing cytotoxic damage to a multitude of signaling molecules associated with the PI3K/Akt pathway in MCF-7 and K562 cancer cells. MC treatment proved to be very efficient in down-regulating NF-kappa B, 14-3-3 proteins, and GRB2 involved in the cell proliferation and differentiation in MCF-7 cells. On the other hand, DMC treatment of MCF-7 cells proved to be more efficient in down-regulating the total Akt level in addition to down-regulating the level of expression of other key players involved in the maintenance of cell survival (such as NFkappa B, HRas, CDC37 and some of the adaptors proteins from the 14-3-3 family). Moreover, DMC treatment of K562 cells proved to be more efficient in inhibiting cell proliferation by down-regulating 14-3-3 proteins. Interestingly, results show that MC and DMC could both induce non-apoptotic cell death by up-regulating Bcl-XL anti-apoptotic protein. Therefore, we propose DMC as another potential pharmacological agent for enhancing the chemotherapeutic activity of other approved drugs for cancer treatment. Consequently, it is expected that novel DMC analogues will be developed to exert a better selectivity and cytotoxicity for the cancer as compared to the normal cells.
The label-free proteomics approach utilized in this research confirmed that integrative cellular and "omics" assays are valuable tools for providing a deeper understanding of the structure-activity relationship of MC and DMC in p53-proficient and p53-deficient cancer cells and is suitable for use in conjunction with other cellular assays for better defining the potential chemotherapeutic potential of DMC, and MC in breast and leukemia cancer. Overall, our results indicate that large-scale proteomic analyses allow for a more fair and accurate prediction of the outcome for different cellular processes, differentially altered by chemotherapeutic drug treatment.
